ENTRY       D12531                      Drug
NAME        Nadofaragene firadenovec (USAN/INN);
            Nadofaragene firadenovec-vncg;
            Adstiladrin (TN)
PRODUCT     ADSTILADRIN (Ferring Pharmaceuticals)
REMARK      Product: D12531<US>
EFFICACY    Antineoplastic
  DISEASE   Bladder cancer [DS:H00022]
  TYPE      Gene therapy product
COMMENT     Recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2bTreatment of non-muscle-invasive bladder cancer resistant to Bacille Calmette-Guerin (BCG)
TARGET      IFNA2 [HSA:3440] [KO:K05414]
  PATHWAY   hsa05200(3440)  Pathways in cancer
BRITE       Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interferons
                IFNA2
                 D12531  Nadofaragene firadenovec (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D12531
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12531
DBLINKS     CAS: 1823059-12-6
///
